About Acumen Pharmaceuticals
Acumen Pharmaceuticals (NASDAQ:ABOS) is a biopharmaceutical company focused on developing novel therapies for the treatment of Alzheimer's disease and related neurodegenerative conditions. Acumen's primary project revolves around targeting and neutralizing amyloid-beta oligomers, which are thought to play a key role in the progression of Alzheimer's disease. The objective of the company is to advance its lead candidate through clinical trials to address the urgent need for effective treatments against Alzheimer's, aiming to improve the quality of life for patients and their families affected by this devastating condition. Acumen Pharmaceuticals is dedicated to pushing the boundaries of neuroscience and biotechnology to bring innovative solutions to the forefront of healthcare.
Snapshot
Operations
Produtos e/ou serviços de Acumen Pharmaceuticals
- Development of ACU193, a monoclonal antibody targeting soluble amyloid-beta oligomers for Alzheimer’s disease treatment.
- Research on new biomarkers for early Alzheimer's diagnosis and monitoring.
- Collaboration on Alzheimer's disease therapeutic research projects with academic and industry partners.
- Investigation into the molecular mechanisms of Alzheimer's disease for novel therapeutic targets.
- Development of advanced diagnostic tools for neurodegenerative diseases.
- Outreach and educational programs for Alzheimer's disease awareness and patient support.
equipe executiva do Acumen Pharmaceuticals
- Mr. Daniel J. O'Connell M.B.A.CEO & Director
- Dr. James Doherty Ph.D.President & Chief Development Officer
- Mr. Matt ZugaCFO & Chief Business Officer
- Dr. Grant A. Krafft Ph.D.Co-Founder
- Dr. Caleb E. Finch Ph.D.Co-Founder
- Dr. William L. Klein Ph.D.Co-Founder
- Mr. Russell Barton M.S.Chief Operating Officer
- Ms. Kelly CarranzaVice President, Finance & Accounting and Corporate Controller
- Ms. Alex Braun M.B.A.VP & Head of Investor Relations
- Mr. Derek M. Meisner Esq., J.D.Chief Legal Officer & Corporate Secretary